Scientists Discover Hidden ‘Master Switch’ That Triggers Skin Cancer and Disables Immunity

Scientists have identified a key protein, HOXD13, that acts as a hidden “master switch” in melanoma, simultaneously promoting tumor growth and helping cancer evade the immune system, according to new research from NYU Langone Health and its Perlmutter Cancer Center published in Cancer Discovery.

The transcription factor HOXD13, normally involved in embryonic development, becomes overactive in melanoma and drives angiogenesis by stimulating pathways that increase blood supply to tumors, including those involving vascular endothelial growth factor (VEGF), semaphorin-3A (SEMA3A), and CD73. This process ensures tumors receive the oxygen and nutrients needed to expand.

In addition to fueling tumor growth, HOXD13 creates an immunosuppressive shield that blocks cancer-fighting T cells from reaching and destroying melanoma cells. Patients with high levels of HOXD13 were found to have fewer cytotoxic T cells in their blood, indicating a direct link between the protein and immune evasion.